- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Vogel on the Utility of Frontline Lenvatinib or Sorafenib in HCC
September 4th 2021, 4:04pm
International Liver Cancer Association Annual Conference
Arndt Vogel, MD, discusses the utility of frontline lenvatinib or sorafenib in hepatocellular carcinoma.
Dr. Singal on the Results of a Mailed Outreach Strategy for Surveillance Utilization in HCC
September 4th 2021, 4:02pm
International Liver Cancer Association Annual Conference
Amit Singal, MD, discusses the results of a study evaluating the utilization of a mailed surveillance outreach program in hepatocellular carcinoma.
Dr. Rich on the Prevalence of Cachexia in HCC
September 4th 2021, 4:01pm
International Liver Cancer Association Annual Conference
Nicole Rich, MD, discusses the prevalence of cachexia in hepatocellular carcinoma.
SIRT With Y90 Plus Chemotherapy Extends Survival for Intrahepatic Cholangiocarcinoma
September 4th 2021, 3:55pm
The addition of selective internal radiation therapy with Y90 resin microspheres to gemcitabine/cisplatin resulted in a median overall survival of 21.6 months for patients with inoperable intrahepatic cholangiocarcinoma, according to prospective phase 2 data.
Dual Checkpoint Blockade/Ablation Regimens Show Intriguing Activity in Advanced HCC
September 4th 2021, 3:35pm
International Liver Cancer Association Annual Conference
Combining durvalumab and tremelimumab plus transcatheter arterial chemoembolization or radiofrequency ablation was found to be both efficacious and safe as a treatment for patients with advanced hepatocellular carcinoma, according to results of a pilot study.
Predictive Biomarkers for Checkpoint Inhibition Remain Unmet Need in HCC
September 3rd 2021, 10:57pm
International Liver Cancer Association Annual Conference
Josep M. Llovet, MD, discusses the importance of identifying biomarkers of response to checkpoint inhibitors for patients with hepatocellular carcinoma, as well as future research directions.
New and Updated Findings Showcase a Shift With Immunotherapy Across Melanoma
August 16th 2021, 1:13pm
Data that emerged from the 2021 ASCO Annual Meeting represent potential paradigm shifts for patients with advanced melanoma.
Non–CAR T-Based Strategies Shake Up the Management of Non-Hodgkin Lymphoma
August 13th 2021, 5:35pm
Pan Pacific Lymphoma Conference
Stephen M. Ansell, MD, PhD, discusses recent progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.
BTK Inhibitors Represent the Preferred Frontline Regimen in CLL
August 13th 2021, 2:00pm
Pan Pacific Lymphoma Conference
The majority of patients with newly diagnosed chronic lymphocytic leukemia have better outcomes with BTK inhibitors compared with standard chemoimmunotherapy, making them the logical choice for frontline therapy.
Zanubrutinib Shows Encouraging Tolerability, Activity in BTK Inhibitor–Intolerant B-Cell Malignancies
August 12th 2021, 7:35pm
Pan Pacific Lymphoma Conference
Zanubrutinib demonstrated clinical activity and tolerability in previously treated patients with B-cell malignancies who were intolerant to therapy with ibrutinib and/or acalabrutinib, according to results of the phase 2 BGB-3111-215 trial.
Standardized Guidelines Support Management Strategies of CAR T-Cell Therapy–Related Toxicities
August 12th 2021, 4:00pm
Pan Pacific Lymphoma Conference
As more CAR T-cell therapies are approved for the treatment of patients with hematologic malignancies, adopting management strategies for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome using newly standardized grading criteria is an important component of utilizing these products in practice.
Acalabrutinib Induces Durable Disease Control in Frontline CLL at 4 Years
August 11th 2021, 6:43pm
Pan Pacific Lymphoma Conference
Acalabrutinib, alone or in combination with obinutuzumab, demonstrated superior efficacy and an acceptable safety profile in patients with treatment-naïve chronic lymphocytic leukemia.
Loncastuximab Tesirine and Ibrutinib Combination Shows Promise in R/R DLBCL and MCL
August 11th 2021, 5:21pm
Pan Pacific Lymphoma Conference
The combination of loncastuximab tesirine-lpyl and ibrutinib displayed encouraging antitumor activity with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma.
Optimal Frontline Hodgkin Lymphoma Treatment Requires Careful Consideration of Toxicities
August 11th 2021, 4:32pm
Pan Pacific Lymphoma Conference
Alison J. Moskowitz, MD, discusses recent developments made in the Hodgkin lymphoma paradigm, shared advice for optimal stratification, and spotlighted potential emerging prognostic markers that might further help to guide treatment decisions.
Ongoing Research Aims to Solidify CAR T-Cell Therapy’s Place in Non-Hodgkin Lymphoma
August 11th 2021, 3:29pm
Pan Pacific Lymphoma Conference
CAR T-cell therapy has proven to be an effective treatment option in non-Hodgkin lymphoma subtypes, such as diffuse large B-cell lymphoma, and mantle cell lymphoma.
Checkpoint Inhibitor/TKI Combos Jump RCC Treatment to Next Level
August 9th 2021, 7:23pm
Five-year survival rates in renal cell carcinoma are drastically improving due to recent regulatory approvals of combination therapies involving checkpoint blockade and VEGF TKIs.
Smarter Screening, Risk Assessments Are Key to Eliminating Racial Disparities in Breast Cancer Outcomes
August 9th 2021, 7:13pm
“Smarter screening” and a better understanding of the breast cancers women of color are more likely to develop are all crucial to helping these patients survive this disease at the same rates as their White counterparts.
With More At-Home Treatments Available, Importance of Medication Adherence Must Be Stressed
August 9th 2021, 6:43pm
With more oral cancer therapies available, the importance of medication adherence and education must be recognized.
Knowledge of Biosimilars Becomes A Necessity in Oncology Nursing
August 9th 2021, 4:34pm
Understanding the functionality and naming convention of biosimilars vs their biologic counterparts are important concepts to utilizing these agents in oncology, according to a presentation given by Teresa Knoop, MSN, RN, AOCN, during the 5th Annual School of Nursing Oncology Meeting.
Immunotherapy, Targeted Therapy, and Novel Strategies Progress Practice in GI Malignancies
August 9th 2021, 1:05pm
Data that were presented during the 2021 ASCO Annual Meeting shed light on new therapeutic strategies, and treatment considerations that are expanding the paradigms of gastrointestinal malignancies.